Brokers Issue Forecasts for CLRB Q2 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Sunday, July 12th. Brookline Capital Markets analyst K. Dolliver forecasts that the biopharmaceutical company will post earnings of ($0.63) per share for the quarter. Brookline Capital Markets has a “Strong-Buy” rating on the stock. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.34) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q3 2026 earnings at ($0.50) EPS and Q4 2026 earnings at ($0.59) EPS.

Cellectar Biosciences (NASDAQ:CLRB) last announced its earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating the consensus estimate of ($1.88) by $0.55.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Cellectar Biosciences to a “hold” rating in a research note on Saturday, June 20th. LADENBURG THALM/SH SH began coverage on Cellectar Biosciences in a research note on Friday, May 15th. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Monday, April 20th. Finally, Roth Capital reiterated a “buy” rating and set a $11.00 target price on shares of Cellectar Biosciences in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cellectar Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Cellectar Biosciences Price Performance

Shares of CLRB stock opened at $2.63 on Wednesday. Cellectar Biosciences has a 12 month low of $2.20 and a 12 month high of $6.52. The firm has a market capitalization of $21.01 million, a P/E ratio of -0.39 and a beta of 0.55. The company’s fifty day moving average price is $2.80 and its two-hundred day moving average price is $2.99.

Institutional Investors Weigh In On Cellectar Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 41,704 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Cellectar Biosciences during the third quarter worth $73,000. Citadel Advisors LLC bought a new position in shares of Cellectar Biosciences in the 3rd quarter worth about $104,000. Sequoia Financial Advisors LLC lifted its position in shares of Cellectar Biosciences by 135.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 14,567 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Cellectar Biosciences by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 3,744 shares during the period. 16.41% of the stock is owned by institutional investors and hedge funds.

Key Cellectar Biosciences News

Here are the key news stories impacting Cellectar Biosciences this week:

• Positive Sentiment: Cellectar published Phase 1 data for iopofosine I 131 showing manageable safety and preliminary antitumor activity, including stable disease or better in most evaluable patients, which supports continued development. Article Title
• Positive Sentiment: Brookline Capital Markets upgraded Cellectar Biosciences to Strong-Buy, reinforcing a more bullish outlook on the stock. Article Title
• Neutral Sentiment: Brookline also issued quarterly and full-year EPS estimates that were in line with the broader consensus, which is not a major surprise but keeps attention on the company’s expected losses and development timeline.
• Negative Sentiment: Short interest in CLRB reportedly rose sharply, signaling that some traders remain skeptical and that volatility could stay elevated. Article Title

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical?stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope?labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B?cell malignancies, including multiple myeloma and non?Hodgkin lymphoma.